AUROPHARMA.NS AUROPHARMA NIFTY_MIDNSE
₹1,426.40
+22.07% 1Y
Market & Price
Market Cap
-
Current Price
₹1,426.40
High / Low (52W)
₹1,546.70 / ₹1,022.20
Beta
-
Valuation
Stock P/E
-
Industry PE
-
Forward P/E
-
PEG Ratio
-
Book Value
₹-
Price to Book
-
P/S
-
EV/EBITDA
-
Dividend Yield
-
Profitability & Returns
ROCE
13.58%
ROE
-
ROA
-
Profit Margin
-
Op Margin
-
EPS (Latest Qtr)
₹15.86
EPS (TTM)
₹-
Balance Sheet & Liquidity
Debt/Equity
-
Quick Ratio
-
Current Ratio
-
Debt
-
Total Assets
₹58,502.15 Cr
Current Assets
₹32,708.75 Cr
Working Capital
₹14,669.74 Cr
Ownership
Promoter Holding
-
Chg in Prom Hold
-
FII / Inst Holding
-
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
-
Total Revenue (TTM)
-
EBITDA
-
Free Cash Flow
-
Operating Cash Flow
-
Shares Outstanding
-
Gross Margin
-
Payout Ratio
-
Growth (CAGR)
Revenue 5Y
10.69%
Profit 5Y
22.05%
Revenue (YoY)
-
Earnings (YoY)
-
PROS
- Compounding revenue at 10.7% over 5 years.
- Profit CAGR of 22.1% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Ad space
Quarterly Results
Figures in INR.
| Metric | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 7,893.15 Cr | 8,381.12 Cr | 7,791.77 Cr | 8,604.51 Cr | 8,751.50 Cr |
| Cost of Revenue | - | 3,315.41 Cr | 3,427.88 Cr | 3,239.22 Cr | 3,481.21 Cr | 3,429.07 Cr |
| Gross Profit | - | 4,577.74 Cr | 4,953.24 Cr | 4,552.55 Cr | 5,123.30 Cr | 5,322.43 Cr |
| Operating Expenses | - | 3,368.46 Cr | 3,605.75 Cr | 3,354.83 Cr | 3,814.69 Cr | 4,000.06 Cr |
| Operating Income | - | 1,209.28 Cr | 1,347.49 Cr | 1,197.72 Cr | 1,308.61 Cr | 1,322.37 Cr |
| EBITDA | - | 1,736.86 Cr | 1,894.54 Cr | 1,710.25 Cr | 1,896.02 Cr | 1,867.39 Cr |
| Interest Expense | - | 118.48 Cr | 115.02 Cr | 97.75 Cr | 92.77 Cr | 98.21 Cr |
| Pretax Income | - | 1,199.85 Cr | 1,335.09 Cr | 1,206.80 Cr | 1,338.52 Cr | 1,290.61 Cr |
| Tax Provision | - | 354.28 Cr | 432.26 Cr | 382.60 Cr | 428.72 Cr | 369.77 Cr |
| Net Income | - | 845.81 Cr | 903.47 Cr | 824.75 Cr | 910.29 Cr | 921.26 Cr |
| Diluted EPS | - | 14.56 | 15.56 | 14.20 | 15.67 | 15.86 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 24,617.13 Cr | 28,704.50 Cr | 31,378.13 Cr | 33,384.74 Cr |
| Cost of Revenue | - | 11,899.70 Cr | 13,236.21 Cr | 13,026.24 Cr | 13,488.36 Cr |
| Gross Profit | - | 12,717.43 Cr | 15,468.29 Cr | 18,351.89 Cr | 19,896.38 Cr |
| Operating Expenses | - | 10,179.83 Cr | 11,026.76 Cr | 13,395.87 Cr | 14,818.77 Cr |
| Operating Income | - | 2,537.60 Cr | 4,441.53 Cr | 4,956.02 Cr | 5,077.61 Cr |
| EBITDA | - | 3,986.03 Cr | 6,139.99 Cr | 7,172.95 Cr | 7,274.01 Cr |
| Interest Expense | - | 128.95 Cr | 268.09 Cr | 457.24 Cr | 383.97 Cr |
| Pretax Income | - | 2,612.50 Cr | 4,379.99 Cr | 5,066.29 Cr | 5,111.85 Cr |
| Tax Provision | - | 684.85 Cr | 1,211.02 Cr | 1,582.72 Cr | 1,608.88 Cr |
| Net Income | - | 1,927.50 Cr | 3,172.97 Cr | 3,485.88 Cr | 3,504.75 Cr |
| Diluted EPS | 45.19 | 32.90 | 54.16 | 59.81 | - |
Compounded Sales Growth
| 5 Years: | 10.69% |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | 22.05% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +22.07% |
| 6 Months: | +18.29% |
| 3 Months: | +23.97% |
| 1 Month: | +2.12% |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 39,889.99 Cr | 45,071.51 Cr | 49,784.97 Cr | 58,502.15 Cr |
| Current Assets | - | 21,545.67 Cr | 24,205.63 Cr | 27,162.46 Cr | 32,708.75 Cr |
| Cash & Equivalents | - | 4,396.29 Cr | 3,393.48 Cr | 5,568.95 Cr | 7,191.40 Cr |
| Inventory | - | 8,511.23 Cr | 9,808.23 Cr | 10,543.72 Cr | 12,052.94 Cr |
| Receivables | - | 4,466.38 Cr | 4,816.74 Cr | 5,745.93 Cr | 7,094.37 Cr |
| Total Liabilities | - | 13,038.14 Cr | 15,220.71 Cr | 17,138.04 Cr | 20,619.34 Cr |
| Current Liabilities | - | 11,493.78 Cr | 12,199.13 Cr | 14,682.34 Cr | 18,039.01 Cr |
| Long Term Debt | - | 618.96 Cr | 2,134.90 Cr | 1,561.65 Cr | 802.75 Cr |
| Total Debt | - | 5,286.21 Cr | 6,647.63 Cr | 8,262.87 Cr | 8,072.84 Cr |
| Total Equity | - | 26,839.85 Cr | 29,842.80 Cr | 32,653.32 Cr | 37,890.97 Cr |
| Shares Outstanding | - | 58.59 Cr | 58.59 Cr | 58.08 Cr | 58.08 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 2,386.75 Cr | 2,434.52 Cr | 3,924.62 Cr | 5,526.37 Cr |
| Investing Cash Flow | - | -3,977.75 Cr | -4,255.95 Cr | -1,875.80 Cr | -3,458.61 Cr |
| Financing Cash Flow | - | 1,814.41 Cr | 800.42 Cr | 119.78 Cr | -1,269.15 Cr |
| Capital Expenditure | - | -2,720.40 Cr | -3,561.50 Cr | -2,519.55 Cr | -3,104.67 Cr |
| Free Cash Flow | - | -333.65 Cr | -1,126.98 Cr | 1,405.07 Cr | 2,421.70 Cr |
| Net Change in Cash | - | 223.41 Cr | -1,021.01 Cr | 2,168.60 Cr | 798.61 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 51.7% | 53.9% | 58.5% | 59.6% |
| Operating Margin % | - | 10.3% | 15.5% | 15.8% | 15.2% |
| Net Margin % | - | 7.8% | 11.1% | 11.1% | 10.5% |
| ROE % | - | 7.2% | 10.6% | 10.7% | 9.2% |
| ROCE % | - | 8.9% | 13.5% | 14.1% | 12.5% |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AUROPHARMA
No recent headlines available.